Cargando…
Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach
The individualized treatment of type 2 diabetes mellitus, using various glucagon-like peptide receptor agonists (GLP1RAs), has recently been described. As experience with existing GLP1RAs grows, and as newer molecules in the development pipeline continue to progress, interest related to these drugs...
Autor principal: | Kalra, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065297/ https://www.ncbi.nlm.nih.gov/pubmed/24549850 http://dx.doi.org/10.1007/s13300-014-0058-y |
Ejemplares similares
-
Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012) -
Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021) -
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021) -
Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
por: Kreiner, Frederik Flindt, et al.
Publicado: (2023) -
Effects of glucagon‐like peptide‐1 receptor agonists on kidney function and safety in type 2 diabetes patients
por: Kim, Min Kyung, et al.
Publicado: (2021)